Cardiovascular Medicine

Influenza infection, Acute myocardial Infarction, Flu Shot during COVID-19 Pandemic in US population. A Review of Literature

1. Nischit Baral
2. Nirajan Nayak

Reviewed by ScreenIT

Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study

1. Kamal Matli
2. Nibal Chamoun
3. Aya Fares
4. Victor Zibara
5. Soad Al-Osta
6. Rabih Nasrallah
7. Pascale Salameh
8. Jacques Mokhbat
9. Georges Ghanem

Reviewed by ScreenIT

Plasma P ‐selectin is an early marker of thromboembolism in COVID ‐19

1. Bánk G. Fenyves
2. Arnav Mehta
3. MGH COVID‐19 Collection & Processing Team
4. Kyle R. Kays
5. Caroline Beakes
6. Justin Margolin
7. Marcia B. Goldberg
8. Nir Hacohen
9. Michael R. Filbin

Reviewed by ScreenIT

Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients after COVID-19

1. Michał Chudzik
2. Monika Burzyńska
3. Joanna Kapusta

Reviewed by ScreenIT

Aorta smooth muscle-on-a-chip reveals impaired mitochondrial dynamics as a therapeutic target for aortic aneurysm in bicuspid aortic valve disease

1. Mieradilijiang Abudupataer
2. Shichao Zhu
3. Shiqiang Yan
4. Kehua Xu
5. Jingjing Zhang
6. Shaman Luo
7. Wenrui Ma
8. Md Fazle Alam
9. Yuyi Tang
10. Hui Huang
11. Nan Chen
12. Li Wang
13. Guoquan Yan
14. Jun Li
15. Hao Lai
16. Chunsheng Wang
17. Kai Zhu
18. Weijia Zhang

• Curated by eLife

  Evaluation Summary:

  The authors developed an aorta-on-a-chip system to investigate the potential mechanism of Bicuspid Aortic Valve-Thoracic Aortic Aneurysm, BAV-TAA, and to test candidate pharmacologic agents. This study is of broad interest to readers in the field of lab-on-a-chip, biomedicine, biomaterials, etc. However, some important details regarding the development of the model are missing, as are some control data. The authors need to discuss the limitations of this model, such as the inability of their on-a-chip model to recapitulate aortic changes associated with complex pathologic processes such as ECM degradation, inflammation, etc, and discuss the importance of follow-up studies in in vivo models.

  (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. The reviewers remained anonymous to the authors.)

Reviewed by eLife

Anticoagulants and Antiplatelets in COVID-19: Impact on Survival and Thromboembolism Development

1. Thomas Salmon
2. Mitchell Titley
3. Zaid Noori
4. Mark Crosby
5. Rajiv Sankaranarayanan

Reviewed by ScreenIT

TEG®, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy

1. Gert Jacobus Laubscher
2. Petrus Johannes Lourens
3. Chantelle Venter
4. Douglas B Kell
5. Etheresia Pretorius

Reviewed by ScreenIT

Heart Rate Variability as a Prospective Predictor of Early COVID-19 Symptoms

1. Alexey Ponomarev
2. Konstantin Tyapochkin
3. Ekaterina Surkova
4. Evgeniya Smorodnikova
5. Pavel Pravdin

Reviewed by ScreenIT

Pulmonary Thromboembolism in Patients After COVID-19: Predictive Indicators for Correct Diagnosis

1. Dilyana Yakova-Hristova
2. Iana Simova
3. Pavlin Pavlov
4. Martin Hristov
5. Todor Kundurzhiev
6. Nikolai Dimitrov
7. Toni Vekov

Reviewed by ScreenIT

Data mining methodology for response to hypertension symptomology—application to COVID-19-related pharmacovigilance

1. Xuan Xu
2. Jessica Kawakami
3. Nuwan Indika Millagaha Gedara
4. Jim E Riviere
5. Emma Meyer
6. Gerald J Wyckoff
7. Majid Jaberi-Douraki

Reviewed by ScreenIT